Brian L Erstad1. 1. Department of Pharmacy Practice and Science, College of Pharmacy, Tucson, Arizona 85721-0207, USA. erstad@pharmacy.arizona.edu
Abstract
OBJECTIVE: To derive recommendations for the dosing of commonly used medications in the morbidly obese patient in the ICU. DATA SOURCES: Articles were obtained through computerized searches involving MEDLINE. The bibliographies of retrieved publications and textbooks were reviewed for additional references. STUDY SELECTION: All studies involving the pharmacokinetics or pharmacodynamics of medications in obese subjects or patients. DATA EXTRACTION: The emphasis was on studies involving morbidly obese patients but, in the absence of such data, investigations involving lesser forms of obesity were extracted. DATA SYNTHESIS: There is a paucity of data upon which to make recommendations for dosing commonly used medications in the morbidly obese patient in the ICU, although recommendations were provided based on the available information. CONCLUSIONS: There is clearly a need for more investigations involving dosing regimens of medications in the morbidly obese population. Until such studies are available, the clinician must try to derive the best dosing regimens for medications based on the limited pharmacokinetic data available for some agents and clinical judgement.
OBJECTIVE: To derive recommendations for the dosing of commonly used medications in the morbidly obesepatient in the ICU. DATA SOURCES: Articles were obtained through computerized searches involving MEDLINE. The bibliographies of retrieved publications and textbooks were reviewed for additional references. STUDY SELECTION: All studies involving the pharmacokinetics or pharmacodynamics of medications in obese subjects or patients. DATA EXTRACTION: The emphasis was on studies involving morbidly obesepatients but, in the absence of such data, investigations involving lesser forms of obesity were extracted. DATA SYNTHESIS: There is a paucity of data upon which to make recommendations for dosing commonly used medications in the morbidly obesepatient in the ICU, although recommendations were provided based on the available information. CONCLUSIONS: There is clearly a need for more investigations involving dosing regimens of medications in the morbidly obese population. Until such studies are available, the clinician must try to derive the best dosing regimens for medications based on the limited pharmacokinetic data available for some agents and clinical judgement.
Authors: M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young Journal: JAMA Date: 1997-05-28 Impact factor: 56.272
Authors: Zachary C Dietch; Therese M Duane; Charles H Cook; Patrick J O'Neill; Reza Askari; Lena M Napolitano; Nicholas Namias; Christopher M Watson; Daniel L Dent; Brandy L Edwards; Puja M Shah; Christopher A Guidry; Stephen W Davies; Rhett N Willis; Robert G Sawyer Journal: Surg Infect (Larchmt) Date: 2016-03-30 Impact factor: 2.150